AR Asset Management Inc. Sells 4,000 Shares of Astrazeneca Plc $AZN

AR Asset Management Inc. lowered its position in shares of Astrazeneca Plc (NYSE:AZN) by 50.0% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 4,000 shares of the company’s stock after selling 4,000 shares during the quarter. AR Asset Management Inc.’s holdings in Astrazeneca were worth $789,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. IHT Wealth Management LLC increased its stake in shares of Astrazeneca by 0.3% during the fourth quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock valued at $3,076,000 after buying an additional 54 shares during the period. Visionary Wealth Advisors boosted its position in Astrazeneca by 1.5% during the 4th quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock valued at $737,000 after acquiring an additional 60 shares in the last quarter. Vista Investment Management boosted its position in Astrazeneca by 0.3% during the 4th quarter. Vista Investment Management now owns 21,215 shares of the company’s stock valued at $3,723,000 after acquiring an additional 60 shares in the last quarter. Kestra Investment Management LLC grew its holdings in shares of Astrazeneca by 1.9% during the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after acquiring an additional 63 shares during the period. Finally, Luken Investment Analytics LLC grew its holdings in shares of Astrazeneca by 4.3% during the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock worth $274,000 after acquiring an additional 64 shares during the period. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Up 0.1%

Shares of Astrazeneca stock opened at $169.52 on Thursday. The company has a market cap of $262.91 billion, a price-to-earnings ratio of 25.45, a price-to-earnings-growth ratio of 1.38 and a beta of 0.24. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The company’s 50 day moving average is $181.13 and its 200 day moving average is $188.13. Astrazeneca Plc has a twelve month low of $142.98 and a twelve month high of $212.71.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The firm had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Research analysts anticipate that Astrazeneca Plc will post 10.22 EPS for the current year.

Analyst Ratings Changes

AZN has been the topic of a number of research reports. Barclays restated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. The Goldman Sachs Group reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Finally, Weiss Ratings downgraded shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 18th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $211.00.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.